International Journal of Clinical Research

Objective To explore the therapeutic effect of omeprazole combined with sucralfate in the treatment of acute hemorrhagic gastritis. Methods 90 patients with acute hemorrhagic gastritis treated in The Fifth Affiliated Hospital of Xinjiang Medical University from September 2022 to August 2023 were selected and included in Group A and Group B, with 45 cases in each group. Group A was treated with omeprazole, while Group B was treated with omeprazole+sucralfate. The clinical indicators, gastric function, inflammatory factor levels, clinical efficacy, and adverse reactions of the two groups were compared. Results The bleeding volume, hemostasis time, and length of hospital stay in Group B were lower than those in Group A (P<0.05); After treatment, the levels of PG I, PG II, and G-17 in both groups decreased (P<0.05), and the levels of PG I, PG II, and G-17 in Group B were lower than those in Group A (P<0.05); The levels of IL-8, TNF-α, and PCT decreased in both groups after medication (P<0.05), and the levels of IL-8, TNF-α, and PCT in Group B were lower than those in Group A (P<0.05); The total effective rate of Group B was higher than that of Group A (P<0.05); The incidence of adverse reactions in the two groups was similar (P>0.05). Conclusion The combination of omeprazole and sucralfate is effective in the treatment of acute hemorrhagic gastritis. It can reduce bleeding volume, shorten hemostasis time and hospitalization days, improve gastric function, alleviate inflammatory reactions, and have fewer adverse reactions. It can be adopted and applied.

Pulmonary space occupying lesions; Puncture biopsy; Pathological diagnosis; Benign and malignant lesions